概述
The current document summarizes the state-of-the-art know-ledge as it relates to management of male lower urinary tract symptoms (MLUTS) secondary to benign prostatic hyperplasia (BPH) by updating the 2018 Canadian Urological Association (CUA) BPH guideline.1 The process continues to highlight the essential diagnostic and therapeutic information in a Canadian context. The information included in this document includes that reviewed for the 2010 guideline and further information obtained from an updated MEDLINE search of the English-language literature (search terms included BPH, alpha-block-ers, 5-alpha reductase inhibitor, anti-cholinergic, beta3 agon-ist, phosphodiesterase type 5 inhibitor [PDE5I], transurethral resection of the prostate [TURP], monopolar, bipolar, open simple prostatectomy, enucleation, GreenLight, photoselect-ive vaporization of the prostate[PVP], Aquablation, Rezum, UroLift, temporarily implanted nitinol device [iTiND]), as well as review of the most recent American Urological Association (AUA)2 and European Association of Urology (EAU) guide-lines.3 References include those of historical importance, but management recommendations are based on literature pub-lished between 2000 and 2021. When information and data is available from multiple sources, the most relevant (usually most recent) article is cited based on committee opinion.
